First Patient Enrolled in Landmark Clinical Study to Assess3D Printed Models for Orthopedic Tumor Removal
Stratasys and Ricoh USA have enrolled the first patient in a clinical study assessing 3D printed models for orthopedic tumor removal. The study aims to evaluate the efficacy of 3D printed anatomical models in preoperative planning compared to traditional CT or MRI scans. This research will examine potential improvements in surgical outcomes, such as reduced blood loss, shorter operating times, and fewer complications. The 12-month, multi-center randomized study will involve up to 150 subjects across three sites, including The Ohio State University Wexner Medical Center and Corewell Health. Successful results could establish 3D printed models as a new standard in tumor removal procedures.
- Enrollment of the first patient in a significant clinical study could indicate timely progress.
- Potential for improved surgical outcomes like reduced blood loss and shorter operating times could positively impact patient recovery and satisfaction.
- If successful, the study could establish 3D printed models as a new standard in tumor removal, possibly expanding Stratasys' market footprint.
- There are inherent risks in clinical trials, including the possibility that 3D printed models may not demonstrate a significant improvement over traditional methods.
Insights
The initiation of a clinical study assessing 3D printed models for orthopedic tumor removal could signify a substantial advancement in medical technology and surgical methodologies. For retail investors, understanding the potential implications of this trial is important.
Firstly, the study's goal to compare 3D printed models with traditional CT or MRI imaging for preoperative planning could offer clearer, more tangible benefits in surgical accuracy and patient outcomes. Reduced blood loss and operating time, as stated, are critical factors in improving surgical success and patient recovery rates. If the study yields positive results, it could set new standards in surgical procedures, impacting a wide range of medical practices beyond orthopedics.
From a business perspective, successful outcomes could lead to increased adoption of 3D printing in healthcare, directly benefiting companies like Stratasys and Ricoh. These companies might see a surge in demand for their 3D printing solutions, translating to potential revenue growth. It's essential to monitor the progress and results over the next 12 months, especially any preliminary findings that might influence market perception.
The collaboration between Stratasys and Ricoh on this clinical study presents an intriguing opportunity for both companies. Stratasys, already a leader in 3D printing, stands to strengthen its position in the lucrative healthcare market. The potential adoption of 3D printed models in preoperative planning could drive substantial revenue growth. For Ricoh, this represents a diversification of its product offerings, potentially enhancing its market footprint and financial stability.
Investors should note the duration and scope of this study—12 months across multiple sites. Positive interim results could stimulate investor confidence and potentially lead to a rise in stock prices. However, it's important to remain cautious and consider the inherent risks associated with clinical trials, such as unexpected complications or inconclusive results.
Additionally, investors should monitor any updates regarding the adoption rates of 3D printing technologies in healthcare. This will provide a clearer picture of the long-term financial implications for both companies.
Stratasys and Ricoh co-sponsor clinical study comparing the efficacy of 3D printed models to traditional CT or MRI scanning for bone tumor excision planning
The joint research aims to demonstrate potential improvements in surgical outcomes, including reduced blood loss, shorter operating time including time under anesthesia, and decreased risk of procedural complications. To do this, clinical outcomes will be compared between an experimental group in which tumors are excised using 3D printed models alongside imaging for planning, and an active comparator group in which tumor excision will be prepped solely with imaging.
Benefits for medical staff and patients
The benefits of 3D printed models in preoperative planning are severalfold and positively impact both medical practitioners and patients alike. Doctors and surgeons benefit from improved and more informed presurgical planning and practicing prior to operations, making complex procedures more efficient, economical and faster. Unlike the limitations of computer images, this enables doctors to represent vital aspects of patient anatomy with life-size physical replicas, granting them the means to simulate procedures and aid in their precision of excision, ultimately reducing the chances of a positive margin. In turn, the availability of accurate 3D printed models to better communicate planned procedures, together with a greatly improved surgical process, helps to improve patient outcome and recovery.
The prospective, multi-center randomized controlled study is expected to run for 12 months and involve up to 150 subjects across three sites. The two sites which have agreed at this time to participate are The Ohio State University Wexner Medical Center and Corewell HealthTM, based in
“Our never-ending mission is to improve patient outcomes, and that starts with preoperative planning,” said Kyle K. VanKoevering, MD Associate Professor, Otolaryngology - Head and Neck Surgery, Ohio State Wexner Medical Center. “We look forward to participating in this study to examine how 3D printed models may help the medical staff better prepare for surgery as well as improve patient education.”
“Being one of the sites to participate in this study puts us on the forefront of demonstrating new technologies that can advance patient care and improve health outcomes,” said Aws Hammad, M.D., clinical faculty of orthopaedic surgery at Corewell Health William Beaumont University Hospital. “Addressing the challenges that come along with bone sarcomas and utilizing the power of patient-specific 3D modeling is a significant step in not only patient education but as an aid to surgeons for more precise surgical procedures.”
According to Erez Ben Zvi, VP Medical at Stratasys, “The collaboration brings together unparalleled experience and innovation in medical imaging and 3D printing and, if successful, may establish anatomical models as a new standard for patient treatment in tumor removal from bones.”
Gary Turner, Managing Director, Additive Manufacturing, Ricoh
About Ricoh
Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support digital transformation of workplaces, workspaces and optimize business performance.
Headquartered in
It is Ricoh's mission and vision to empower individuals to find Fulfillment through Work by understanding and transforming how people work so we can unleash their potential and creativity to realize a sustainable future.
For further information, please visit www.ricoh.com.
About Stratasys
Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.
To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including Stratasys’ websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626817575/en/
Investor and Media Contacts:
Stratasys Corporate &
Chris Reese
Chris.Reese@stratasys.com
+1 6651 357 0877
Jonathan Wake / Samantha White,
Incus Media
Stratasys@Incus-Media.com
+44 1737 215200
Stratasys Corporate &
Erik Snider
Erik.Snider@stratasys.com
+972 74 745 6053
Investor Relations
Yonah Lloyd
Yonah.Lloyd@stratasys.com
+972 74 745 4919
Erica Massini
Erica.Massini@stratasys.com
+55 (11) 2626-9229
Kalyani Dwivedi
Kalyani.Dwivedi@stratasys.com
+91 80 6746 2606
Source: Stratasys
FAQ
What is the purpose of the clinical study involving Stratasys (SSYS) and Ricoh?
When did Stratasys (SSYS) and Ricoh enroll the first patient in their clinical study?
How long will the Stratasys (SSYS) and Ricoh clinical study run?
How many subjects will be involved in the Stratasys (SSYS) and Ricoh clinical study?
What potential benefits might the Stratasys (SSYS) clinical study demonstrate?
